In conclusion, considering the failure of a phase I therapy in RA patients who have to initiate an anti-TNF-α regime as a phase II therapy, having efficient response-predictive markers such as pharmacogenetic markers could help patients know ahead of time whether the drug is likely to benefit and be safe for them without facing the complications associated with anti-TNF-α drugs. Here, TNF is linked to rheumatoid arthritis.